A one-year trial evaluating the efficacy and safety of the ALK house dust mite allergy immunotherapy tablet in adult subjects with house dust mite allergic rhinitis.

Trial Profile

A one-year trial evaluating the efficacy and safety of the ALK house dust mite allergy immunotherapy tablet in adult subjects with house dust mite allergic rhinitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
  • Indications Allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Acronyms MERIT
  • Sponsors ALK-Abello
  • Most Recent Events

    • 31 Aug 2015 According to an ALK-Abello media release, the company has obtained approval for the house dust mite sublingual allergy immunotherapy tablet (HDM-SLIT) against allergic rhinitis and allergic asthma in 11 European countries.
    • 09 Feb 2015 According to an ALK-Abello media release, ALK's regulatory filing for HDM SLIT-tablet have been accepted for review by the European health authorities; approval is expected in the fourth quarter of 2015.
    • 09 Jun 2014 Results from this trial were presented at the 2014 Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI), according to the ALK-Abello media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top